Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Meningitis Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Meningitis Overview | 9 | 1 |
| Pipeline Products for Meningitis Comparative Analysis | 10 | 1 |
| Meningitis Therapeutics under Development by Companies | 11 | 1 |
| Meningitis Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Meningitis Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Meningitis Products under Development by Companies | 16 | 1 |
| Meningitis Products under Investigation by Universities/Institutes | 17 | 1 |
| Meningitis Companies Involved in Therapeutics Development | 18 | 9 |
| Adenium Biotech ApS | 18 | 1 |
| Amplyx Pharmaceuticals, Inc. | 19 | 1 |
| Chiesi Farmaceutici SpA | 20 | 1 |
| ContraFect Corporation | 21 | 1 |
| Genticel S.A. | 22 | 1 |
| LG Life Science LTD. | 23 | 1 |
| Matinas BioPharma Holdings, Inc. | 24 | 1 |
| Sanofi Pasteur SA | 25 | 1 |
| Viamet Pharmaceuticals, Inc. | 26 | 1 |
| Meningitis Therapeutics Assessment | 27 | 9 |
| Assessment by Monotherapy Products | 27 | 1 |
| Assessment by Target | 28 | 2 |
| Assessment by Mechanism of Action | 30 | 2 |
| Assessment by Route of Administration | 32 | 2 |
| Assessment by Molecule Type | 34 | 2 |
| Drug Profiles | 36 | 18 |
| amphotericin B Drug Profile | 36 | 2 |
| AP-114 Drug Profile | 38 | 1 |
| CF-302 Drug Profile | 39 | 1 |
| CF-303 Drug Profile | 40 | 1 |
| CF-305 Drug Profile | 41 | 1 |
| CF-309 Drug Profile | 42 | 1 |
| Eupenta Drug Profile | 43 | 1 |
| LBVD Drug Profile | 44 | 1 |
| meningitis vaccine Drug Profile | 45 | 1 |
| meropenem Drug Profile | 46 | 1 |
| pneumococcal [serotype 4, 6A] vaccine Drug Profile | 47 | 1 |
| Small Molecules to Inhibit Pkh2-02 for Cryptococcal Meningitis Drug Profile | 48 | 1 |
| Streptococcus pneumonia vaccine Drug Profile | 49 | 1 |
| tuberculous meningitis vaccine Drug Profile | 50 | 1 |
| viral vaccine Drug Profile | 51 | 1 |
| VT-1129 Drug Profile | 52 | 2 |
| Meningitis Dormant Projects | 54 | 1 |
| Meningitis Discontinued Products | 55 | 1 |
| Meningitis Product Development Milestones | 56 | 6 |
| Featured News &Press Releases | 56 | 1 |
| Jun 01, 2016: Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis | 56 | 1 |
| Sep 16, 2015: FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis | 56 | 1 |
| Apr 24, 2015: Viamet to Provide Update on VT-1129, Novel Antifungal Program at ECCMID 2015 | 57 | 1 |
| Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta | 57 | 1 |
| Sep 11, 2014: Viamet Receives Orphan Drug Designation for VT-1129 | 58 | 1 |
| Oct 25, 2010: Phase III data show that Novartis meningococcal vaccine Menveo demonstrated robust immunogenicity in infants | 58 | 1 |
| Jun 08, 2010: Novartis receives Health Canada approval of Menveo to prevent meningococcal disease | 58 | 1 |
| Mar 18, 2010: Novartis receives approval in the European Union for Menveo, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease | 59 | 1 |
| Feb 22, 2010: Novartis receives FDA approval of Menveo, a vaccine to prevent meningococcal disease | 59 | 1 |
| Jun 30, 2009: Novartis receives Complete Response letter from the US Food and Drug Administration for its investigational vaccine Menveo | 60 | 1 |
| May 06, 2008: Novartis Menveo vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial | 60 | 1 |
| Jan 09, 2008: New data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants | 60 | 1 |
| Nov 15, 2007: New data for Menveo vaccine show excellent immune response and broad protection for infants against meningococcal meningitis | 61 | 1 |
| Appendix | 62 | 2 |
| Methodology | 62 | 1 |
| Coverage | 62 | 1 |
| Secondary Research | 62 | 1 |
| Primary Research | 62 | 1 |
| Expert Panel Validation | 62 | 1 |
| Contact Us | 62 | 1 |
| Disclaimer | 63 | 1 |